Suchergebnisse - "Fasching, Peter A."

PubPharm (1.196)

1

Baseline CD4+ and expansion of γδ T cells correlate with response to durvalumab in triple-negative breast cancer patients

enthalten in: Clinical and translational medicine | 2024

von Massa, C. | Karn, T. | Weber, K. | +19

2

Disentangling the relationships of body mass index and circulating sex hormone concentrations in mammographic density using Mendelian randomization

enthalten in: Breast cancer research and treatment | 2024

von Haas, C. | Chen, H. | Harrison, T. | +36

3

Polygenic Risk Modelling for Prediction of Epithelial Ovarian Cancer Risk

enthalten in: bioRxiv.org | 2024

von Dareng, E. | Tyrer, J. | Barnes, D. | +255

4

ABC7 Consensus : Assessment by a German Group of Experts

enthalten in: Breast care (Basel, Switzerland) | 2024

von Ditsch, N. | Untch, M. | Fasching, P. | +12

5

Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial

enthalten in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society | 2024

von Lorusso, D. | Mouret-Reynier, M. | Harter, P. | +27

6

Disease-free survival as a surrogate for overall survival in HR+/HER2- early breast cancer : A correlation analysis

enthalten in: European journal of cancer (Oxford, England : 1990) | 2024

von Untch, M. | Pérol, D. | Mayer, E. | +10

7

Ribociclib plus Endocrine Therapy in Early Breast Cancer

enthalten in: The New England journal of medicine | 2024

von Slamon, D. | Lipatov, O. | Nowecki, Z. | +28

8

Primary results of the AGO-Zervix-1 Study : A prospective, randomized phase III study to compare the effects of paclitaxel and topotecan with those of cisplatin and topotecan in the treatment of patients with recurrent and persistent cervical cancer

enthalten in: Gynecologic oncology | 2024

von Gass, P. | Thiel, F. | Häberle, L. | +17

9

Efficacy and safety of everolimus plus exemestane in patients with hormone receptor-positive, HER-2-negative advanced breast cancer : Results from the open-label, multicentre, non-interventional BRAWO study

enthalten in: International journal of cancer | 2024

von Lüftner, D. | Schuetz, F. | Schneeweiss, A. | +14

10

Genome-wide association analyses of ovarian cancer patients undergoing primary debulking surgery identify candidate genes for residual disease

enthalten in: NPJ genomic medicine | 2024

von Ramachandran, D. | Tyrer, J. | Kommoss, S. | +77

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[120]